Clinical trials: Invasive Aspergillosis
Mycoses
PK/PD Study of Posaconazole for Empiric Treatment of Invasive Fungal Infections in Neutropenic Patients or Treatment of Refractory Invasive Fungal Infections (Study P01893)
This phase II study will be conducted to: 1. evaluate the pharmacokinetics, safety, tolerance, and efficacy of different dosing schedules of Posaconazole in immunocompromised hosts with a variety of refractory invasive fungal…
- Trial name
- NCT00034671
- Testing
- Posaconazole oral suspension
- Volunteers
- 98 people
- Sponsor
- Merck Sharp & Dohme LLC
Invasive Aspergillosis
Assessment of Varying Oral Dosing Regimens for F901318 in Healthy Subjects
A Phase I, open label study evaluating safety, tolerability and pharmacokinetics of F901318 in healthy subjects following up to 28 days dosing, where F901318 is given orally .
- Trial name
- NCT03340597
- Testing
- F901318
- Where
- United Kingdom
- Volunteers
- 45 people, healthy volunteers welcome
- Sponsor
- F2G Ltd
Aspergillosis
Trial of Micafungin (FK463) in Combination With Liposomal Amphotericin B (AmBisome) for Aspergillosis
The purpose of this study is to evaluate the safety and effectiveness of micafungin in combination with AmBisome as first-line therapy in the treatment of invasive aspergillosis.
- Trial name
- NCT00047827
- Testing
- Micafungin, Liposomal Amphotericin B
- Where
- 7 sites in United States
- Volunteers
- 2 people
- Sponsor
- Astellas Pharma Inc
Invasive Aspergillosis
Study of Potential for Interaction of Fluconazole With F901318
This will be an open label study in two parts. In the first part, F901318 (dose 2 mg/kg IV over 4 hours, Day 1) will be followed by F901318 (2 mg/kg IV over 4 hours) given on Day 8, after dosing with fluconazole 800 mg daily for…
- Trial name
- NCT02730442
- Testing
- F901318, Fluconazole
- Where
- United Kingdom
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- F2G Ltd
Invasive Aspergillosis
Posaconazole (MK-5592) Intravenous and Oral in Children With Invasive Aspergillosis (IA) (MK-5592-104)
This study will evaluate the safety, efficacy, and pharmacokinetics of posaconazole (POS) intravenous (IV) and oral formulations in pediatric participants 2 to <18 years of age with invasive aspergillosis (IA).
- Trial name
- NCT04218851
- Testing
- Posaconazole IV, Posaconazole PFS, Posaconazole tablet
- Where
- 29 sites in United States, Belgium and 8 more
- Volunteers
- 31 people
- Sponsor
- Merck Sharp & Dohme LLC
Aspergillosis
Trial of Combination Antifungal Therapy (Vori+Mica vs. Vori+Placebo) in Invasive Aspergillosis
The purpose of this study is to evaluate the therapeutic effectiveness of combination antifungal therapy (CAT) of voriconazole plus micafungin versus voriconazole plus placebo equivalent as primary therapy for invasive…
- Trial name
- NCT01207128
- Testing
- Voriconazole, micafungin
- Where
- 2 sites in United States
- Sponsor
- University of Arkansas
Invasive Candidiasis, Mucocutaneous Candidiasis
Study to Evaluate the Efficacy and Safety of Ibrexafungerp in Patients With Fungal Diseases That Are Refractory to or Intolerant of Standard Antifungal Treatment
This is a multicenter, open label, non-comparator, single arm study to evaluate the efficacy and safety of ibrexafungerp (SCY-078) in patients ≥ 18 years of age with a documented fungal disease that has been intolerant or…
- Conditions
- Invasive Candidiasis, Mucocutaneous Candidiasis, Coccidioidomycosis, Histoplasmosis
- Trial name
- FURI (NCT03059992)
- Testing
- Ibrexafungerp
- Where
- 37 sites in United States, Austria and 6 more
- Volunteers
- 233 people
- Sponsor
- Scynexis, Inc.
Aspergillosis Invasive, Fungal Infection
Individualized First Maintenance Doses of Voriconazole Through a Multiparametric Algorithm
The goal of this interventional single-arm study is to evaluate the interest of a multiparametric algorithm for individualization of first voriconazole maintenance doses for improvement of initial voriconazole exposure in adult…
- Conditions
- Aspergillosis Invasive, Fungal Infection, Hematologic Malignancy
- Trial name
- VORIPRECI (NCT06582186)
- Testing
- Individualization of first voriconazole maintenance doses
- Where
- France
- Volunteers
- 30 people
- Sponsor
- University Hospital, Grenoble
Mycoses
Study of Posaconazole in the Treatment of Invasive Fungal Infections (Study P02095)
This study is designed to evaluate the safety, tolerance and efficacy of Posaconazole (SCH 56592) under an open label, treatment protocol for subjects with invasive fungal infections: A.
- Trial name
- NCT00034632
- Testing
- Posaconazole oral suspension
- Sponsor
- Merck Sharp & Dohme LLC
Aspergillosis Invasive, Mucormycosis
Study on Theraputic Drug Monitoring and Phamacokinetics of Isavuconazole in Children
The goal of this clinical trial is to learn the plasma concentration of isavuconazole in pediatric patients. It will also learn about the relationship of isavuconazole plasma concentrations to efficacy and safety in pediatric…
- Trial name
- NCT06440915
- Testing
- Theraputic drug monitoring, Isavuconazole
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Shanghai Children's Medical Center
Fever, Mycoses
Phase I Study of the Safety, Tolerance, and Pharmacokinetics of FK463 in Immunocompromised Children With Fever and Neutropenia
The objective of this study is to evaluate the safety, tolerance, and pharmacokinetics of FK463, a novel echinocandin (cell wall-active antifungal lipopeptide), as early empirical therapy for prevention of fungal infections in…
- Conditions
- Fever, Mycoses, Neutropenia
- Trial name
- NCT00001790
- Testing
- FK463
- Where
- United States
- Volunteers
- 120 people
- Sponsor
- National Cancer Institute (NCI)
Aspergillosis, Invasive Pulmonary
PCR Based Detection of Azole Resistance in A. Fumigatus to Improve Patient Outcome.
A standard treatment protocol for invasive aspergillosis (IA) will be implemented in several academic hematology centers in the Netherlands in which a diagnostic test demonstrating azole resistance by multiplex real-time…
- Trial name
- AzorMan (NCT03121235)
- Testing
- PCR based detection of azole resistance in A. fumigatus
- Where
- 8 sites in Netherlands
- Volunteers
- 320 people
- Sponsor
- Erasmus Medical Center
Fungal Infections, Invasive Pulmonary Aspergillosis
A Study of the Safety and Efficacy of Posaconazole Versus Voriconazole for the Treatment of Invasive Aspergillosis (MK-5592-069)
The purpose of this study is to evaluate the safety and efficacy of posaconazole (POS) versus voriconazole (VOR) in the treatment of adults and adolescents with invasive aspergillosis (IA).
- Trial name
- NCT01782131
- Testing
- Posaconazole, Voriconazole
- Volunteers
- 585 people
- Sponsor
- Merck Sharp & Dohme LLC
Invasive Pulmonary Aspergillosis
Value of Amphotericin B Inhalation for Prophylaxis of Invasive Pulmonary Aspergillosis After Renal Transplantation
The purpose of this study is to determine whether inhalation with aerosolized amphoterin B 10mg/d is more effective than aerosolized amphoterin B 2mg/d to reduce the incidence of invasive pulmonary aspergillosis.
- Trial name
- NCT00986713
- Testing
- Amphotericin B
- Where
- China
- Volunteers
- 400 people
- Sponsor
- Capital Medical University
Invasive Pulmonary Aspergillosis
Non-invasive Tools to Diagnose Invasive Aspergillosis Infections in ICU Patients With COVID-19 and Other Conditions.
Invasive aspergillosis (IA) are difficult to diagnose in the ICU population, as the patients often do not present the conventional risks factors of immunocompromised patients (EORTC/MSG criteria).
- Trial name
- BM-ASP-ICU (NCT05138666)
- Testing
- respiratory sample, blood sample
- Where
- France
- Volunteers
- 363 people
- Sponsor
- Centre Hospitalier Universitaire de Besancon
Invasive Aspergillosis
Evaluation of the Potential for Cytochrome P450 3A4 Inhibition by F901318 Using Oral Midazolam as a Probe
Open label evaluation of potential interaction of F901318 with cytochrome P450 3A4 using midazolam as a probe. Twenty healthy male subjects will participate
- Trial name
- NCT02680808
- Testing
- Midazolam with F901318
- Where
- United Kingdom
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- F2G Ltd
Influenza With Pneumonia, Aspergillosis Invasive
Invasive Pulmonary Aspergillosis Complicating Influenza Infection
Study the incidence and outcome of invasive pulmonary aspergillosis (IPA) in ICU patients with severe influenza and in influenza-negative control patients with severe community-acquired pneumonia
- Trial name
- NCT03391492
- Where
- 2 sites in Belgium
- Volunteers
- 298 people
- Sponsor
- Universitaire Ziekenhuizen KU Leuven
Pulmonary Aspergillosis
Azole-resistance in Aspergillus
Prospective multi-center surveillance study on the prevalence of azole-resistant Aspergillus spp. in clinical isolates of patients with pulmonary colonization or invasive infections in Switzerland
- Trial name
- NCT03443336
- Where
- Switzerland
- Volunteers
- 400 people
- Sponsor
- University Hospital, Basel, Switzerland
Survival After IPA, Risk Factors for IPA
Diagnosis of Invasive Pulmonary Aspergillosis (IPA) in Critically Ill Patients
Invasive pulmonary aspergillosis (IPA) is difficult to diagnose and remains a cause of high morbidity and mortality in critically ill patients in the ICU.
- Trial name
- DipA (NCT01866020)
- Where
- Germany
- Volunteers
- 85 people
- Sponsor
- Universitätsklinikum Hamburg-Eppendorf
Aspergillosis, Candidiasis
Voriconazole to Prevent Systemic Fungal Infections in Children
This study will examine how children's bodies metabolize and eliminate the anti-fungal drug voriconazole. The results will yield information needed to make recommendations for safe and effective dosing of the drug in children.
- Conditions
- Aspergillosis, Candidiasis, Fungal Diseases, Mycoses
- Trial name
- NCT00005912
- Testing
- Voriconazole
- Where
- United States
- Volunteers
- 48 people
- Sponsor
- National Cancer Institute (NCI)